HER2 Levels May Aid In Treatment Selection For Metastatic Breast Cancer, Norris Comprehensive Cancer Center and Hospital Study

EurekAlert! -- PHILADELPHIA – Findings published in the December 1, 2008, issue of Clinical Cancer Research, a journal of the American Association for Cancer Research, show lapatinib benefits women with HER2-positive breast cancer, while women with HER2-negative breast cancer or those who express EGRF alone derive no incremental benefit. In addition, a misclassification of metastatic breast cancer patients by as much as 10 percent prevents some people from receiving optimal therapy.

Back to news